Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. The trial is also expected to be conducted in Sweden, Poland, Latvia, Estonia, Croatia, and Bulgaria. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
Ensuring patient safety in clinical trials requires team effort
The development of new drugs and treatments is a long […]
The expanding landscape of Immuno-Oncology – benefits and challenges
I am sure we all have been or will be […]
Crown CRO’s second CRA training successfully completed
Last year, Crown CRO launched a CRA training program that […]
Rescuing a clinical study that has lost one or more of its wheels
An over 30-year long career within clinical research and development […]
The best way to empower girls is through education
Every year on the 11th of October, the International Day […]